Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 13/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 12/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 12/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503607 | 0.77 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2HCAR2MEN1 | |
| SCHEMBL27869257 | 0.76 | MEN1 (0.43) | TAS1R3TAS1R1TAS1R2HCAR2MEN1 | |
| SCHEMBL1067000 | 0.76 | MAPT (0.37) | HCAR2GPR35MAPTNOTUM | |
| Hydrochloric Acid SCHEMBL6740806 | 0.75 | TAS1R3 (0.45) | TAS1R3TAS1R1TAS1R2HCAR2MEN1 | |
| SCHEMBL27805263 | 0.75 | TAS1R3 (0.45) | TAS1R3TAS1R1TAS1R2HCAR2MEN1 | |
| SCHEMBL2470702 | 0.75 | TAS1R3 (0.45) | TAS1R3TAS1R1TAS1R2HCAR2MEN1 | |
| SCHEMBL18781916 | 0.75 | KMO (0.37) | TAS1R3TAS1R1TAS1R2HCAR2KMT2A | |
| SCHEMBL2860749 | 0.73 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL27841030 | 0.73 | MAPT (0.41) | HCAR2MEN1KMT2ACRHBPCRHR2 | |
| SCHEMBL21251402 | 0.73 | TAS1R3 (0.35) | TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524909-B2 | Tetrahydro-pyran derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | GLRA1, GRIA1, GLRA2 | TAS1R3 1170/4885TAS1R1 500/4885TAS1R2 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.